42 results about "Minocycline" patented technology

The invention relates to an isopentenyl-alpha-pyrone dimer Hyperumonates D-F as well as a preparation method and application thereof, and belongs to the field of medical chemistry, the isopentenyl-alpha-pyrone dimer Hyperumonates D-F is obtained by extracting and separating from leaves and branches of Hypericum monogynum for the first time, and the structural formula of the isopentenyl-alpha-pyrone dimer Hyperumonates D-F is D-F. The invention further discloses a preparation method of the isopentenyl-alpha-pyrone dimer Hyperumonates D-F. The isopentenyl-alpha-pyrone dimer Hypericumonates D-F has the advantages that the compounds D-E have remarkable inhibition effects on generation of NO in mouse microglial cells (BV-2 cells) induced by lipopolysaccharide (LPS), the activity of the compounds D-E is higher than that of positive medicine minocycline, and the compounds D-E have application potentials in the field of neuroinflammation medicines, and the invention also relates to a pharmaceutical composition which comprises the isopentenyl-alpha-pyrone dimer Hypericumonates D-F and can be used for preparing medicines for treating neuroinflammation. And pharmaceutically acceptable auxiliary materials, wherein the pharmaceutical composition has the effect of resisting neuroinflammation.

To provide a novel tetracycline derivative having reduced antimicrobial activity for use in treating disorders of the central nervous system.SOLUTION: Provided are novel molecules comprising a modified tetracycline molecule including Deamino Diacetyl Minocycline, Methyl Ether Minocycline, Ethyl Ether Minocycline, Propyl Ether Minocycline, Butyl Ether Minocycline, Butyl Ether Monoacetyl Minocycline, Butyl Ether Diacetyl Minocycline, Butyl Ether Triacetyl Minocycline, or Butyl Ether Tetra Acetyl Minocycline, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, and tautomers thereof, and methods for using the same to treat Alcohol Use Disorder (AUD), Substance Use Disorder (SUD), tobacco use, pain, or proinflammatory disorders.SELECTED DRAWING: None

The application belongs to the technical field of medicine, and relates to a use of minocycline in preparation of an antitumor synergist. The minocycline, as the antitumor synergist, has a synergistic effect with 5-fluorouracil and gemcitabine, significantly enhances the curative effect of an antitumor drug, reduces the dosage of the antitumor drug, and reduces side effects of the antitumor drug on the body or damage of the antitumor drug to normal tissue cells.

The present application relates to a method of treating an inflammatory skin condition by administering a pharmaceutical composition comprising a reduced dose of minocycline to a subject in need thereof, wherein said administration provides an effective plasma or interstitial fluid concentration of minocycline for treating the inflammatory skin condition.

The invention belongs to the technical field of medicines, and relates to application of minocycline in preparation of an anti-tumor synergist. The minocycline is used as an anti-tumor synergist and has a synergistic effect with the 5-fluorouracil and the gemcitabine, so that the curative effect of the anti-tumor medicine is remarkably enhanced, the dosage of the anti-tumor medicine is reduced, and the body side effect caused by the anti-tumor medicine or the damage to normal tissue cells is reduced.

Resorbable implants comprising poly(butylene succinate) and copolymers thereof have been developed. The implants implants are preferably sterilized, and contain less than 20 endotoxin units per device as determined by the limulus amebocyte lysate (LAL) assay, and are particularly suitable for use in procedures where prolonged strength retention is necessary, and can include one or more bioactive agents. The implants may be made from fibers and meshes of poly(butylene succinate) and copolymers thereof, or by 3d printing, and the fibers may be oriented. Coverings and receptacles made from forms of poly(butylene succinate) and copolymers thereof have also been developed for use with cardiac rhythm management devices and other implantable devices. These coverings and receptacles may be used to hold, or partially / fully cover, devices such as pacemakers and neurostimulators. The coverings and receptacles are made from meshes, webs, lattices, non-wovens, films, fibers, and foams, and contain antibiotics such as rifampin and minocycline.

The present invention discloses a strain of Acinetobacter spp. LDH6-2 and its application in degrading tetracycline antibiotics. The LDH6-2 strain was deposited in Guangdong Province Microbial Culture Collection Center on November 23, 2023, with a deposit number of GDMCC NO: 64034. The Acinetobacter spp. LDH6-2 of the present invention is different from other reported strains at the genomic level. It is a new type of Acinetobacter species, which has tetracycline antibiotic degradation ability and can significantly degrade tetracycline, minocycline and tigecycline within 24 h, and the degradation rate of the newly listed eravacycline reaches (75.8 ± 2.9)%, and has good application prospects in the degradation of residual tetracycline antibiotics in water and soil environments.

The invention discloses an AcrB efflux pump inhibitor with a membrane permeabilization effect as well as a preparation method and application thereof. The AcrB efflux pump inhibitor is a solvent compound, an enantiomer, a diastereoisomer, a tautomer or a mixture of a compound with a structure as shown in a formula I or pharmaceutically acceptable salt of the compound, wherein R is C6-C16 straight chain or branched chain alkyl, alkenyl, ester group, amide or substituted phenyl; x is N or C; y is N or C. The compound provided by the invention has better efflux inhibition activity, and the minimum inhibitory concentration can be reduced by 64 times when the compound is combined with minocycline for use.

The invention belongs to the technical field of biological medicine, and particularly relates to a nano-micelle preparation loaded with minocycline and application of the nano-micelle preparation to treatment of cerebral hemorrhage, the nano-micelle preparation is prepared by taking a polyethylene glycol-polycaprolactone nano material PEG3000-PCL2000 as a carrier, and jointly loading minocycline MINO and a CD147 monoclonal antibody Anti-CD147, so that the nano-micelle preparation is prepared. And the bionic nano-drug MINO (at) PNM (at) CD147 with an active targeting function is constructed. The nano-micelle preparation has a brain targeting property and can be enriched in cerebral hemorrhage tissues, so that the local drug concentration and the treatment efficiency are remarkably improved; the traditional Chinese medicine composition can improve neurological impairment caused by cerebral hemorrhage and significantly reduce the volume of cerebral hematoma, and has an obvious treatment effect on cerebral hemorrhage; the number of inflammatory cells in the peripheral area of hematoma and expression of inflammatory mediators can be remarkably reduced, and therefore the inflammatory response in cerebral hemorrhage tissue is relieved.

The invention discloses injectable hydrogel for treating periodontitis as well as a preparation method and application of the injectable hydrogel. The injectable hydrogel is prepared from the following raw materials: chitosan and derivatives thereof, oxidative modified natural polysaccharide and modified hydroxyapatite, the modified hydroxyapatite comprises hydroxyapatite, and the surface of the hydroxyapatite is modified with a metal polyphenol network. The modified hydroxyapatite has multiple functions of oxidation resistance, immunoregulation, osteogenesis promotion, migration promotion, tube formation promotion, antibiosis and the like, and can be combined with the injectable hydrogel with biological adhesion and self-healing performance to realize better in-vivo tissue healing. The injectable hydrogel of the composite functional hydroxyapatite nanoparticles synthesized by the invention has biocompatibility, oxidation resistance, immunoregulation performance, osteogenesis promotion performance and antibacterial performance, and can realize better alveolar bone regeneration and repair in a rat periodontitis model, and the effect of the injectable hydrogel is superior to that of clinically common minocycline.

The invention disclosed herein provides a method for treating Community-Acquired Bacterial Pneumonia (CABP) using 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, in either oral or IV doses or a combination of both.

A pharmaceutical composition for treating moderate or severe rosacea comprises a formulated, body weight-independent low dose of minocycline that reduces the severity of rosacea in at least 2 weeks with a decrease in lesion count, Investigator's Global Assessment (IGA) score, and Clinician's Erythema Assessment (CEA) score with a measured improvement in quality of life.

To provide a method for treating Community-Acquired Bacterial Pneumonia (CABP).SOLUTION: A method comprises administering, to a subject, 9-[(2,2-dimethyl-propylamino)-methyl]-minocycline or a salt thereof according to a following dosing regimen: (1) three intravenous doses of about 100 mg each, which are administered every 12 hours; (2) subsequent optional one or more intravenous doses of about 100 mg each, each of which is administered 24 hours after the immediate preceding intravenous dose; (3) subsequent optional one oral dose of about 300 mg, which is administered in the morning and 12-24 hours after the immediate preceding intravenous dose; and (4) subsequent optional one or more oral doses of about 300 mg each, each of which is administered 24 hours after the immediate preceding oral dose.SELECTED DRAWING: Figure 1

To provide methods for treating bacterial infection of skin or skin structure.SOLUTION: Provided is a method for treating bacterial infection of skin or skin structure in a human subject in need thereof, the method comprising a step of orally administering to the subject 9-[(2,2-dimethyl-propylamino)-methyl]-minocycline or a salt thereof at a dose of about 450 mg per day for consecutive two days, then at a dose of about 300 mg per day for five days or longer.SELECTED DRAWING: None

A pharmaceutical composition for treating moderate or severe rosacea comprises a formulated, body weight-independent low dose of minocycline that reduces the severity of rosacea in at least 2 weeks with a decrease in lesion count, Investigator's Global Assessment (IGA) score, and Clinician's Erythema Assessment (CEA) score with a measured improvement in quality of life.

Methods and compositions for treating bacterial infections using tetracycline compounds are described. For example, in one embodiment, the invention provides a method for treating an infected subject, comprising administering an effective amount of 9-[(2,2-dimethylpropylamino)-methyl]-minocycline or a salt thereof to said subject to treat said subject, wherein 9-[(2,2-dimethylpropylamino)-methyl]-minocycline is orally administered for two consecutive days at a dose of about 450 mg / day, followed by administration for five or more days at a dose of about 300 mg / day.

The present invention relates to a composition for preventing or treating periodontal disease and a dental composite antibiotic ointment composition. The composition for preventing or treating periodontal disease according to the present invention comprises minocycline and metronidazole as effective ingredients.

The invention discloses an alpha-pyrone mixed source meroterpenoid dimer Hypericumonates A-C as well as a preparation method and application of the alpha-pyrone mixed source meroterpenoid dimer Hypericumonates A-C, and belongs to the technical field of medical chemistry. The alpha-pyrone mixed source meroterpenoid dimer Hypericumonates A-C has a structure as shown in formulas A-C, and the alpha-pyrone mixed source meroterpenoid dimer Hypericumonates A-C is obtained by being separated from Hypericum monogynum for the first time. The alpha-pyrone mixed source meroterpenoid dimer Hypericumonates A-C has a structure as shown in formulas A-C; the compound Hypericumonates A-C has obvious inhibitory activity on NO concentration in BV-2 cells induced by lipopolysaccharide (LPS), shows an obvious anti-inflammatory effect, has the activity higher than that of a positive control drug minocycline, can inhibit expression of iNOS and COX-2 in a dose-dependent manner, and can be applied to preparation of anti-neuroinflammation drugs.

The application is suitable for the technical field of drug synthesis, and provides a continuous flow preparation method and system of a secondary amine derivative of C9 position of omadacycline, the method is that minocycline C9-amino methylate, alkyl aldehyde compound and tertiary amine acid acceptor are dissolved in an organic solvent to form a raw material liquid, hydrogen is continuously introduced into a microreactor filled with a solid palladium carbon catalyst, and a reductive amination reaction is carried out under the condition of 50-70 DEG C and 1.0-2.5 MPa, the residence time of the material is 10-30 minutes, and high-purity product is obtained after post-treatment. The special system includes a feeding module, a mixing and preheating module, a microreaction module, a detection and control module and a product collection module, and each module cooperates to realize continuous and high-precision reaction. The application solves the defects of low efficiency, high safety risk and unstable product quality of the traditional kettle process, the product yield is more than 95%, the HPLC purity is higher than 98.5%, and the application is intrinsically safe, easy to industrialize, and environmentally friendly.

The invention provides nitrate reducing bacteria C381 as well as a method and application thereof. The nitrate reducing bacteria C381 is preserved in China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.36842; the invention provides a novel oral cavity probiotic nitrate reducing bacteria C381, the nitrate reducing bacteria C381 has an inhibition effect on periodontal disease bacteria, and the nitrate reducing bacteria C381 is sensitive to antibiotics such as erythromycin, piperacillin, minocycline, doxycycline, cefazolin, tetracycline, amikacin, gentamicin, vancomycin and cefoperazone, and can be used for preparing oral cavity probiotics for treating periodontal disease bacteria. And the product has good survival ability in the oral cavity.

The invention relates to the technical field of medicines, in particular to a tannic acid / Cu < 2 + > / minocycline compound and application thereof. The preparation method of the compound comprises the following steps: complexing tannic acid (TA) and Cu < 2 + >, and loading minocycline (MH) by taking the complex as a carrier. The TA-Cu / MH prepared by the preparation method disclosed by the invention has multiple effects of resisting bacteria, resisting oxidation, resisting inflammation and the like, and also has good safety and a certain effect of promoting tissue regeneration. The research provides an experimental basis for application of a multifunctional drug in periodontitis treatment, and is beneficial to promoting precise drug treatment of periodontitis.

The invention provides bacillus C367 as well as a method and application thereof. The bacillus C367 is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.36841; the bacillus C367 is separated from the Inner Mongolia cheese; the bacillus C367 can be used for preparing medicines for treating or preventing periodontal diseases; the invention provides a novel oral cavity probiotic bacillus C367, the bacillus C367 has an inhibition effect on periodontal disease bacteria, and the bacillus C367 is sensitive to antibiotics such as minocycline, amikacin, tetracycline, erythromycin, cefoperazone, streptomycin, kanamycin, gentamicin, vancomycin and ceftriaxone, and has good survival ability in an oral cavity.

Provided herein are molecules, compositions and methods for treating an ocular disease or disorder, comprising: administering to a subject an aqueous pharmaceutical composition, wherein the composition comprises a molecule, or a pharmaceutically acceptable salt thereof, and having reduced or no antimicrobial activity, wherein the molecule is selected from at least one of structure A, B, C, or D having the R-groups listed for each. The ocular disease or disorder is selected from the group consisting of abnormal angiogenesis, choroidal neovascularization (CNV), age-related macular degeneration (AMD), neovascular (exudative) age-related macular degeneration (nAMD), diabetic retinopathy, retinal vascular permeability, retinal edema, diabetic retinopathy, diabetic macular edema (DME), CNV associated with nAMD, sequela, associated with retinal ischemia, central retinal vein occlusion, and posterior segment neovascularization.

The present invention relates to the field of assisted reproductive technology, and particularly relates to the use of minocycline or its derivatives in promoting in vitro maturation of oocytes. Since it is important to promote nuclear and cytoplasmic maturation during the process of oocytes resuming meiosis in vitro in the IVM technology, cytoplasmic maturation is the key factor affecting embryonic developmental potential. The research of the present invention has found that the application of MiH in the IVM culture medium not only facilitates nuclear maturation and helps improve the extrusion of the first polar body of oocytes, but also balances the damage of ROS to cytoplasmic organelles and the nucleus, which is beneficial to the maturation of oocyte cytoplasm. At the same time, it improves the blastocyst formation rate of fertilized eggs of aged mouse oocytes. Adding MiH to the IVM culture medium may become a new method to improve and optimize the IVM technology, which is of great significance for improving the fertility of elderly women and the development of clinical reproductive medicine.

The present application relates to a kind of isoprenyl-alpha-pyrone dimer Hypericumonates D-F and its preparation method and application, belong to the field of medicinal chemistry, the isoprenyl-alpha-pyrone dimer Hypericumonates D-F is first extracted from the leaves and branches of Hypericum monogynum Isolation, its structural formula is D-F formula.Compounds D-E has significant inhibitory effect on the NO production in mouse microglial cells (BV-2 cells) induced by lipopolysaccharide (LPS), and its activity is stronger than that of positive drug minocycline, with the potential application in the field of neuroinflammatory drugs, the present application simultaneously relates to a kind of pharmaceutical composition, it includes above-mentioned isoprenyl-alpha-pyrone dimer Hypericumonates D-F, and pharmaceutically acceptable adjuvant, it has the efficacy of anti-neuroinflammation.

The invention relates to the technical field of medicines, and discloses a minocycline-containing composition and application of the minocycline-containing composition in preparation of a product for treating acne. 0.5%-2% of allantoin; 5%-9% of vitamin C; 2%-3% of vitamin E; 3%-7% of collagen; 1%-1.5% of a grape seed extract; 0.2% to 0.5% of ceramide; 0.5%-2.2% of trehalose; 0.6%-1.1% of a purslane extract; the product for treating acne comprises the following raw materials: 66%-70% of the composition, 2%-7% of tea tree essential oil, 6%-11% of tranexamic acid, 5%-9% of arbutin, 4%-7% of recombinant human epidermal growth factors and 0.4%-0.8% of a preservative and pure water, a water phase, an oil phase and active ingredients are constructed, gradient mixing is performed, and the composition containing minocycline is prepared. The composition is mixed with raw materials of a product for treating acne, and the finally prepared product can be used for treating acne, repairing scars and recovering skin vitality.

The invention discloses a portable agar dilution method for detecting helicobacter pylori in-vitro drug sensitive batten and a method for detecting helicobacter pylori. The portable agar dilution method comprises a porous plate, agar and antibiotics, and the agar and the antibiotics are arranged in holes of the porous plate; the antibiotics comprise clarithromycin, amoxicillin, levofloxacin, metronidazole, rifampicin, tetracycline and minocycline; and the antibiotics are respectively arranged in different holes. An agar dilution method is adopted for in-vitro drug sensitivity, and six antibiotics required by CLSI and EUCAST and clinically common minocycline, negative quality control and positive quality control detection are integrated, so that inconvenience and waste caused by using a large number of 9cm plates for detection are avoided, and portable detection of helicobacter pylori in-vitro drug sensitivity is realized.

The application discloses application of total flavones of radix scutellariae combined with tetracycline antibiotics in preparation of products against staphylococcus aureus, and belongs to the technical field of medicines. The application provides an antibacterial composition containing total flavones of radix scutellariae and tetracycline antibiotics, aiming at the problems of high drug resistance rate and great toxic side effects of tetracycline antibiotics in the treatment of staphylococcus aureus and methicillin-resistant staphylococcus aureus infection. The total flavones of radix scutellariae contain more than 89% of flavones, and contain various active ingredients such as baicalin and baicalein. The tetracycline antibiotics are selected from doxycycline or minocycline. In vitro experiments prove that the combination of the two has a significant synergistic antibacterial effect on staphylococcus aureus and drug-resistant staphylococcus aureus, and the dosage of doxycycline or minocycline can be reduced by 75%, thereby effectively reducing the toxic side effects.